For good-risk metastatic RCC patients, who are considered not a candidate for cytoreductive nephrectomy, systemic therapy with one of the IO/TKI combinations is indicated, taking into consideration the patient’s comorbidity and tolerance to the regimen. (For non-clear cell metastatic RCCs, sys...

The IMDC criteria were created to be prognostic but not predictive of treatment response. Until or unless a predictive biomarker is found, all treatment options listed could be appropriate (although the use of nivolumab and ipilimumab may not be approved by insurance), and a shared decision should b...